RxDoctor Payments Data

Terilyn Scott-Winful, MD

Gastroenterology · Plano, TXNPI 1942315460

Payments from drug & device makers

$30,405in general payments, 2019–2025

Across 575 payments — averaging $52.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Novo Nordisk$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$401
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$371
  • Merck$366
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$18,60061%
  • Travel & lodging$1,2914%
  • Food & beverage$10,43934%
  • Education$760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,405 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$60,205
Medicare patients
290
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$167,222
OcalivaObeticholic Acid15$141,827
CreonLipase/Protease/Amylase17$49,406
OzempicSemaglutide34$37,341
LinzessLinaclotide25$35,395
TrulicityDulaglutide12$14,350
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates92$5,684
Azathioprine19$4,416
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,693
Omeprazole181$3,053
Lubiprostone23$2,939
Sucralfate13$2,390
Pantoprazole Sodium100$1,142
Topiramate76$841
Famotidine59$821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$162$141,82715 claims
AbbVieCreon, Linzess$18,611$84,80042 claims
Novo NordiskOzempic$6,341$37,34134 claims
Lilly USA, LLCTrulicity$242$14,35012 claims
Ferring Pharmaceuticals Inc.Clenpiq$107$3,69322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →